Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 17, 2017. The report details the vesting outcomes of Deferred Bonus Awards and Matching Awards granted in 2014 under the 2009 Deferred Annual Bonus Plan (DABP). The three-year performance period for these awards concluded on December 31, 2016, with vesting notifications issued on February 16, 2017.
Key Financial Metrics and Performance Outcomes
The filing does not report consolidated revenue, profit, cash flow, or debt metrics. Instead, it focuses on executive compensation performance metrics tied to the 2014 awards:
- Adjusted Free Cash Flow: The Company did not meet the threshold level of performance for the three-year period. Result: Lapsed in full (0% vesting).
- Total Shareholder Return (TSR): GSK ranked 9th (below median) against a comparator group of 10 global pharmaceutical companies. Result: Lapsed in full (0% vesting).
- R&D New Products Sales: Achieved sales of £6.717 billion, exceeding the maximum vesting level of £4.428 billion (threshold was £3.623 billion). Adjustments were made for the Novartis transaction. Result: Vested in full (33.33% vesting).
- Total Vesting Outcome: 66.67% of the 2014 awards lapsed; 33.33% vested.
Share Prices at Vesting (Feb 16, 2017):
- Ordinary Share: £16.17
- American Depositary Share (ADS): $40.92
Material Changes and Transactions
The primary material event is the release of shares to Persons Discharging Managerial Responsibilities (PDMRs) based on the partial vesting described above. The filing lists specific transactions for nine executives, including CEO Sir Andrew Witty and CEO Designate Ms Emma Walmsley. All transactions were recorded at a price of £0.00 or $0.00, representing the release of restricted shares rather than a market purchase.
| Executive | Position | Instrument | Total Shares/ADS Released |
|---|---|---|---|
| Sir Andrew Witty | CEO | Ordinary Shares | 90,488 |
| Ms Emma Walmsley | CEO Designate | Ordinary Shares | 19,814 |
| Mr R G Connor | President, Global Manufacturing & Supply | Ordinary Shares | 17,712 |
| Mr S Dingemans | CFO | Ordinary Shares | 29,931 |
| Mr S A Hussain | President, Global Pharmaceuticals | Ordinary Shares | 12,991 |
| Mr D S Redfern | Chief Strategy Officer | Ordinary Shares | 16,154 |
| Dr M M Slaoui | Chairman, Global Vaccines | ADS | 28,860 |
| Ms C Thomas | SVP, Human Resources | Ordinary Shares | 10,023 |
| Mr P C Thomson | SVP, Communications & Government Affairs | Ordinary Shares | 6,037 |
| Mr D E Troy | SVP & General Counsel | ADS | 11,682 |
| Dr P J T Vallance | President, R&D | Ordinary Shares | 35,817 |
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the performance conditions of the awards. The document notes that the R&D New Products sales measure was adjusted for the implications of the "three-part transaction with Novartis," indicating that corporate restructuring impacts were factored into the performance calculation.
Key Facts for Investor Verification
- Performance Shortfall: Verify the impact of missing the Adjusted Free Cash Flow and TSR thresholds on total executive compensation costs for the period.
- R&D Success: Confirm the £6.717 billion New Product sales figure and the specific adjustments made regarding the Novartis transaction.
- Leadership Transition: Note the vesting of awards for Ms Emma Walmsley in her capacity as "CEO Designate," signaling the transition of leadership from Sir Andrew Witty.
- Share Dilution: Assess the total number of shares released (approx. 262,500 Ordinary Shares and 40,542 ADSs) against the company's total share capital to understand dilution impact.